Revenue remains highly erratic and dependent on milestone recognition, with quarterly R&D spending consistently exceeding revenue, reaching a peak expenditure of $34.7M in 2025Q2.
| Sales/Revenue | 21.61M | 10M | 10.59M | 8.08M | 8.61M | 3.64M | 0 | 0 |
| Revenue Growth % | 131.5% | -5.55% | 30.99% | -6.14% | 136.79% | - | - | - |
| Cost of Goods Sold | 9.91M | 2.03M | 2.06M | 1.96M | 841K | 0 | 13K | 6K |
| COGS % of Revenue | - | 20.29% | 19.46% | 24.19% | 9.77% | - | - | - |
| Gross Profit | 11.7M | 7.97M | 8.53M | 6.13M | 7.77M | 3.64M | -13K | -6K |
| Gross Margin % | 54.15% | 79.71% | 80.54% | 75.81% | 90.23% | 100% | - | - |
| Gross Profit Growth % | - | -6.53% | 39.16% | -21.14% | 113.67% | 28076.92% | -116.67% | - |
| Operating Expenses | 168.69M | 165.64M | 107.38M | 79.11M | 74.86M | 36.57M | 4.83M | 3.77M |
| OpEx % of Revenue | - | 1656.38% | 1014.12% | 978.68% | 869.28% | 1005.39% | - | - |
| Selling, General & Admin | 42.56M | 41.77M | 41.05M | 26.14M | 22.26M | 10.33M | 1.79M | 772K |
| SG&A % of Revenue | - | 417.71% | 387.67% | 323.39% | 258.5% | 284% | - | - |
| Research & Development | 127.65M | 125.9M | 68.39M | 54.92M | 53.44M | 26.24M | 3.04M | 3M |
| R&D % of Revenue | - | 1258.96% | 645.9% | 679.48% | 620.54% | 721.39% | - | - |
| Other Operating Expenses | -1.47M | -2.03M | -2.06M | -1.96M | -841K | 0 | 0 | 0 |
| Operating Income | -156.98M | -157.67M | -98.85M | -72.98M | -67.09M | -32.93M | -4.84M | -3.77M |
| Operating Margin % | -726.34% | -1576.67% | -933.58% | -902.87% | -779.04% | -905.39% | - | - |
| Operating Income Growth % | - | -59.51% | -35.45% | -8.78% | -103.74% | -579.93% | -28.43% | - |
| EBITDA | -154.95M | -155.64M | -96.79M | -71.02M | -66.25M | -32.82M | -4.83M | -3.77M |
| EBITDA Margin % | -716.94% | -1556.38% | -914.12% | -878.68% | -769.28% | -902.28% | - | - |
| EBITDA Growth % | -38.93% | -60.8% | -36.27% | -7.21% | -101.88% | -579.42% | -28.29% | - |
| D&A (Non-Cash Add-back) | 2.03M | 2.03M | 2.06M | 1.96M | 841K | 113K | 13K | 6K |
| EBIT | -135.59M | -113.63M | -98.85M | -72.98M | -67.09M | -32.93M | -6.58M | -3.77M |
| Net Interest Income | 66.09M | 44.04M | 29.85M | 14.69M | 4.03M | 257K | 0 | 0 |
| Interest Income | 66.09M | 44.04M | 29.85M | 14.69M | 4.03M | 257K | 206K | 233K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 206K | 233K |
| Other Income/Expense | 42.51M | 44.04M | 29.85M | 14.69M | 4.03M | 257K | -1.94M | -233K |
| Pretax Income | -114.48M | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.78M | -4M |
| Pretax Margin % | -529.67% | -1136.25% | -651.62% | -721.18% | -732.22% | -898.32% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -114.48M | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.78M | -4.24M |
| Net Margin % | -529.67% | -1136.25% | -651.62% | -721.18% | -732.22% | -898.32% | - | - |
| Net Income Growth % | -47.25% | -64.69% | -18.36% | 7.56% | -93.01% | -381.6% | -60.11% | - |
| Net Income (Continuing) | -114.48M | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.78M | -4M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.83 | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 | -0.10 |
| EPS Growth % | -35.29% | -42.97% | 3.03% | 13.16% | -92.41% | -393.75% | -60% | - |
| EPS (Basic) | - | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 | -0.10 |
| Diluted Shares Outstanding | 62.67M | 61.97M | 53.75M | 44.02M | 41.47M | 41.24M | 41.61M | 41.61M |
| Basic Shares Outstanding | 62.67M | 61.97M | 53.75M | 44.02M | 41.47M | 41.24M | 41.61M | 41.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical trial execution failure
As indicated by the quarterly financial data, JANX's revenue trajectory remains highly volatile, characterized by intermittent milestone recognition that reached $10.0M in 2025Q3 before receding, reflecting a business model entirely dependent on the successful achievement of R&D hurdles rather than recurring commercial product sales.
The absence of consistent top-line growth suggests that the company's revenue is a byproduct of collaboration accounting rather than market-driven demand. Investors should interpret these fluctuations as indicators of operational progress in clinical partnerships rather than as a sustainable foundation for future valuation.
Based on reported income statements, JANX has seen its quarterly R&D expenditure climb from $12.2M in 2023Q4 to a peak of $34.7M in 2025Q2, demonstrating a clear commitment to accelerating clinical development that significantly outstrips the company's ability to generate offsetting collaboration-based revenue.
The persistent rise in R&D spending highlights the capital-intensive nature of advancing the TRACTr platform through human trials. This trend suggests that management is prioritizing pipeline velocity over near-term expense discipline, which may necessitate frequent capital raises to maintain the current operational trajectory.
According to the provided financial statements, JANX consistently utilizes significant stock-based compensation, reaching $11.0M in 2025Q2, which effectively obscures the true cash-based operational deficit and complicates the assessment of the company's underlying burn rate relative to its actual scientific output.
The reliance on equity-based incentives suggests a strategy to preserve cash while attracting specialized talent, yet it creates a disconnect between reported net losses and actual cash outflows. Analysts should monitor the ratio of stock-based compensation to total operating expenses to gauge the true economic cost of maintaining the current research infrastructure.
As reported in recent filings, the company's reliance on non-recurring milestone payments to fund a rapidly expanding R&D budget creates a precarious financial position, where any delay in clinical milestones could lead to a rapid depletion of liquidity in a high-interest rate environment.
The lack of a diversified revenue stream leaves the company highly exposed to sector-specific downturns in oncology funding. This structural dependency warrants caution, as the current cash position may prove insufficient if the transition from Phase 1 to Phase 2 trials encounters unexpected regulatory or clinical hurdles.
Quick answers to the most common questions about buying JANX stock.
For fiscal year 2025, Janux Therapeutics, Inc. (JANX) reported total revenue of $10.0M.
Janux Therapeutics, Inc. (JANX) reported a net loss of $113.6M for the fiscal year ending 2025.
Janux Therapeutics, Inc. (JANX) reported an operating income of $-157.7M, resulting in an operating profit margin of -1576.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Janux Therapeutics, Inc. (JANX) generated $8.0M in gross profit for the year, representing a gross profit margin of 79.7%. This demonstrates the company's core pricing power and production efficiency.